U.S. Software Stock News

Sesame Workshop has filed a lawsuit against United Parks & Resorts (NYSE:PRKS), alleging unpaid royalties and contractual breaches tied to Sesame Place attractions. The suit seeks to terminate the long running licensing agreement and obtain damages related to the use of the Sesame Street brand in United Parks & Resorts themed entertainment portfolio. The dispute centers on the Sesame Place branded parks, which rely on access to Sesame Workshop intellectual property and characters for their...

Mid-America Apartment Communities (MAA) has been drawing attention after recent share price pressure, with the stock showing negative returns over the past month, past 3 months and year. That slump is prompting closer scrutiny from income-focused REIT investors. See our latest analysis for Mid-America Apartment Communities. The latest share price of US$126.32 leaves Mid-America Apartment Communities with a 7-day share price return of a 4.9% decline and a year-to-date share price return of a...

Earlier this month, Vericel Corporation received U.S. FDA approval to begin commercial manufacturing of its MACI cartilage repair therapy at its new Burlington, Massachusetts cell therapy facility starting in the second quarter of 2026, expanding capacity for symptomatic knee cartilage defect treatment in adults. This manufacturing approval not only supports higher MACI production volumes but also strengthens Vericel’s ability to pursue potential commercialization of the therapy in markets...

Halcyon has integrated its technology with Freddie Mac's Asset and Income Modeler (AIM) to support automated dual source income assessment for self employed borrowers. The solution combines borrower provided tax returns with IRS transcripts, automating data validation for lenders using Freddie Mac loans. The capability is immediately available to approved lenders, allowing faster adoption in current mortgage underwriting workflows. For investors watching Federal Home Loan Mortgage...

If you are trying to work out whether Ocular Therapeutix at around US$8.76 is a bargain or just fairly priced, starting with a clear view of its valuation can help frame your next move. The stock has seen mixed returns, with a 14.7% decline over the last 7 days and a 4.4% decline over the last 30 days, while the 1 year return sits at 13.5% and the 3 year return at 76.6%, compared with a 57.6% decline over 5 years. Recent market attention on Ocular Therapeutix has focused on its progress as...

How BioMarin Pharmaceutical’s Recent Moves Set Up a Closer Look at Value Before we get into the numbers, if you are wondering whether BioMarin Pharmaceutical’s current share price fairly reflects its long term potential, it helps to first step back and see what the market has been doing with the stock lately. BioMarin’s share price closed at US$58.51 most recently, with returns of 4.3% decline over the past week, 3.0% decline over the past month, a 1.6% decline year to date, and a 15.7%...

Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference, showing multi-year stabilization of patient function and a favorable safety profile in a disease with no approved therapies. An unusually high 99% of eligible participants from earlier sevasemten trials chose to continue into the MESA extension, underscoring sustained engagement with the investigational...

If you are wondering whether Veralto, at around US$90.20, is offering fair value right now or if the market is mispricing it, this article walks you through what the numbers actually say. The stock has recently been under pressure, with a 7 day return of a 4.4% decline, a 30 day return of a 5.1% decline and a year to date return of an 8.4% decline, adding to a 1 year return of a 7.5% decline. Recent coverage around Veralto has focused on how the newly listed business fits into the broader...

If you are wondering whether Terex shares are still offering value at current levels, you are not alone. This article will walk through what the market price might be implying about the business. The stock last closed at US$59.41, with returns of 8.0% year to date and 49.4% over the past year. However, a 4.3% decline over the last week and a 14.0% decline over the last month shows sentiment has recently cooled. These short term moves sit against a longer backdrop where Terex has also...

Exelixis recently reported quarterly adjusted earnings per share that exceeded expectations, helped by higher Cabometyx volumes and lower operating expenses, while the FDA accepted its New Drug Application for zanzalintinib in metastatic colorectal cancer with a target action date in December 2026. Alongside these results, the company reiterated its 2026 guidance and benefited from multiple upward analyst earnings estimate revisions, underscoring how regulatory milestones and disciplined...

CRH plans to delist its ordinary and preference shares from the London Stock Exchange, subject to shareholder approval. If approved, the company will maintain a sole primary listing on the New York Stock Exchange under the ticker NYSE:CRH. The move is intended to consolidate trading in one market and could affect how different groups of investors access and trade the shares. NYSE:CRH currently trades at $99.82, with the share price showing a 4.1% gain over the past year and a 132.7% return...

NGL Energy Partners LP recently closed a seven-year US$950 million senior secured term loan facility and amended its asset-based revolving credit facility, using the proceeds to repay existing borrowings, repurchase a portion of its Class D Preferred Units, and for general corporate purposes. This refinancing reshapes the partnership’s mix of debt and preferred equity, with the targeted repurchase of about 195,000 Class D units signaling a push for a simpler, more flexible capital...

If you are wondering whether Teradata's current share price offers good value or not, you are in the right place because this article focuses squarely on what the numbers say about the stock. Teradata shares last closed at US$26.58, with a 7 day return of a 5.1% decline, a 30 day return of a 29.8% decline, and a 1 year return of a 17.1% gain, which gives you a sense of both recent setbacks and longer term recovery. Recent attention on Teradata has been shaped by ongoing interest in data and...

FIGS (NYSE:FIGS) is partnering with US lawmakers on the Healthcare is Human Act, a bipartisan federal bill. The proposed legislation would offer tax credits to healthcare professionals working in shortage areas. The effort is aimed at addressing workforce shortages and burnout in critical healthcare settings. FIGS, best known for its premium medical scrubs and apparel, is closely tied to the everyday realities of healthcare workers. By stepping into the policy arena through the Healthcare...

If you are wondering whether Ulta Beauty's share price still makes sense after its recent swings, this article will walk through what the current market tag might be telling you about the stock's value. The shares most recently closed at US$535.72, after a 17.1% decline over the last 7 days and a 21.6% decline over the last 30 days, set against a 49.9% return over the past year. Recent price moves have come alongside ongoing attention on Ulta Beauty's position in the US specialty retail...

Wondering if Symbotic at around US$49.43 is still a compelling opportunity or already pricing in a lot of optimism? This article is going to focus squarely on what the current share price implies about the company’s value. Over the past week the stock returned 1.7%, while the 30 day return was a 15.4% decline and the year to date return was a 23.8% decline, set against a 128.3% return over the last year and 164.0% over three years. Recent coverage around Symbotic has largely focused on its...

If you are wondering whether WSFS Financial at around US$62.72 is still offering value or starting to look fully priced, you are not alone. The stock has had a mixed run recently, with a 0.4% decline over the last 7 days and a 7.3% decline over 30 days, set against stronger returns of 13.9% year to date, 22.1% over 1 year, 68.9% over 3 years and 28.5% over 5 years. Recent coverage has focused on the bank's positioning in its regional markets and how investors are weighing those fundamentals...

Antero Midstream (NYSE:AM) has completed a US$1.1b acquisition of Marcellus midstream assets. The transaction expands the company’s midstream footprint and capacity in a key U.S. natural gas region. Management expects 2026 adjusted EBITDA and free cash flow after dividends to be 8% and 11% higher, respectively, versus prior expectations. The business continues to operate under fixed-fee, take-or-pay contracts that reduce direct exposure to commodity price swings. For you as an investor,...

Expedia Group (NasdaqGS:EXPE) has integrated PredictHQ data into its platform to track and anticipate fan driven travel linked to major events across North America. The partnership focuses on measuring incoming demand on specific routes and in host cities, including triple digit growth in both international and domestic accommodation spending tied to large events. This data driven approach is intended to help Expedia and its partners adjust targeting, pricing, and inventory management around...

If you are wondering whether Nexa Resources at around US$10.95 is still offering value after its recent run, you are not alone. This article will focus on what the current price might imply. The stock has returned 0.7% over the last 7 days and 24.6% year to date, with a 112.9% return over the past year, even though the 30 day return sits at an 11.6% decline. Recent news flow around Nexa Resources has centered on broader sector sentiment, funding conditions and company-specific operational...

In March 2026, Custom Truck One Source reported mixed fourth-quarter and full-year 2025 results, with record quarterly revenue of US$528.18 million and full-year revenue of US$1.94 billion but a wider annual net loss of US$31.05 million, while earnings per share in the quarter beat market expectations despite a revenue miss. Management highlighted record rental fleet utilization near 84%, new OEM partnerships, and 2026 guidance calling for 3% to 9% revenue growth and higher adjusted EBITDA,...

Quarterly beat and restructuring set the stage for Charles River Laboratories stock Charles River Laboratories International (CRL) recently beat quarterly expectations and introduced a new US$1b share repurchase authorization, while simultaneously restructuring through divestitures, site closures, and workforce reductions. See our latest analysis for Charles River Laboratories International. Despite the recent beat, Charles River Laboratories International's 1 day share price return of 1.83%...

If you are looking at Samsara and wondering whether the current share price lines up with the underlying business, this article will walk through what the numbers suggest about value. The stock last closed at US$31.72, with returns of a 10.3% decline over the past week, 14.3% over the past month, a 6.5% decline year to date and a 16.7% decline over the past year, while the 3-year return sits at 66.8%. Recent coverage around Samsara has focused on its position in connected operations software...

If you are wondering whether Baxter International's current share price reflects its underlying worth, you are not alone. This article is designed to help you assess exactly that. The stock last closed at US$17.40, after returns of a 1.6% decline over 7 days, 21.9% decline over 30 days, 10.8% decline year to date, 49.0% decline over 1 year, 50.4% decline over 3 years, and 76.0% decline over 5 years. These moves have come alongside ongoing attention on Baxter International's position in the...